<DOC>
	<DOC>NCT03011749</DOC>
	<brief_summary>The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity</brief_summary>
	<brief_title>Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Metastatic castration resistant prostate cancer Eligible for Radium223 therapy Informed consent Inability to understand study protocol Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Radium-223 therapy</keyword>
</DOC>